GlassScriptPhysician profile
Joseph Owens
NPI 1326579285
$5,151.91
in general payments reported to CMS, 2019-2025
20 companies · $3,139 in 2025
The $3,139 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $112 · 2022: $457 · 2023: $559 · 2024: $885 · 2025: $3,139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,699 · Travel and Lodging: $883 · Education: $1.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,698.64 |
| Travel and Lodging | $882.75 |
| Education | $1.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $2,915.41 | 2022-2025 | Sapien 3 Ultra Resilia, Pascal |
| Boston Scientific Corporation | $631.27 | 2024-2025 | General - Therapies, Avvigo Guidance System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $267.87 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $188.71 | 2023-2024 | Xarelto |
| Cvrx, INC. | $169.30 | 2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $165.60 | 2023-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $140.81 | 2022-2024 | Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $137.18 | 2022-2025 | Lifevest |
| Abbvie INC. | $125.00 | 2025 | |
| Lantheus Medical Imaging, INC. | $75.60 | 2021 | |
| Novartis Pharmaceuticals Corporation | $71.75 | 2025 | |
| Abiomed | $55.24 | 2023-2025 | Impella |
| Abbott Laboratories | $42.26 | 2025 | Navitor, Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $34.22 | 2025 | Ffrangio |
| Biosense Webster, INC. | $32.83 | 2025 | Carto 3 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $25.01 | 2025 | Angio-Seal, Metacross Otw, Glidewire |
| Merck Sharp & Dohme LLC | $24.79 | 2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $21.36 | 2025 | Onpattro |
| Pfizer INC. | $14.15 | 2021 | |
| Amgen INC. | $13.55 | 2025 | Repatha |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Owens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.